NURIX THERAPEUTICS INC's ticker is NRIX and the CUSIP is 67080M103. A total of 122 filers reported holding NURIX THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 0.01 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $217,313 | -22.3% | 27,648 | -1.2% | 0.00% | 0.0% |
| Q2 2023 | $279,690 | +7.6% | 27,997 | -4.4% | 0.00% | 0.0% |
| Q1 2023 | $259,962 | -27.2% | 29,275 | -9.9% | 0.00% | 0.0% |
| Q4 2022 | $356,872 | -20.3% | 32,502 | -5.5% | 0.00% | 0.0% |
| Q3 2022 | $448,000 | +42.7% | 34,395 | +38.7% | 0.00% | 0.0% |
| Q2 2022 | $314,000 | -44.6% | 24,793 | -38.8% | 0.00% | 0.0% |
| Q1 2022 | $567,000 | -51.6% | 40,500 | 0.0% | 0.00% | -50.0% |
| Q4 2021 | $1,172,000 | -3.4% | 40,500 | 0.0% | 0.00% | -33.3% |
| Q3 2021 | $1,213,000 | +12.9% | 40,500 | 0.0% | 0.00% | +50.0% |
| Q2 2021 | $1,074,000 | +120.1% | 40,500 | +158.0% | 0.00% | +100.0% |
| Q1 2021 | $488,000 | -5.4% | 15,700 | 0.0% | 0.00% | 0.0% |
| Q4 2020 | $516,000 | – | 15,700 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ponoi II Management, LLC | 561,574 | $16,825,000 | 24.93% |
| Ponoi Management, LLC | 561,573 | $16,825,000 | 14.94% |
| TRV GP III, LLC | 2,422,549 | $72,580,000 | 13.78% |
| Foresite Capital Management IV, LLC | 1,205,798 | $36,126,000 | 5.32% |
| Foresite Capital Management V, LLC | 451,522 | $13,528,000 | 4.20% |
| WestHill Financial Advisors, Inc. | 283,333 | $8,489,000 | 2.62% |
| DAFNA Capital Management LLC | 306,320 | $9,177,000 | 2.44% |
| Bain Capital Life Sciences Investors, LLC | 1,284,314 | $38,478,000 | 2.39% |
| REGENTS OF THE UNIVERSITY OF CALIFORNIA | 571,212 | $17,113,000 | 2.02% |
| Redmile Group, LLC | 3,093,077 | $92,669,000 | 1.62% |